Search

Addressing the bureaucracy challenge

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research.

Read more

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and differences of myeloid neoplasms.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias.

Read more

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more